FDA files motion to dismiss Teva suit on exclusivity loss for generic Cozaar

The US FDA has filed a motion to dismiss Teva Pharmaceutical Industries' recent lawsuit regarding the loss of its first-filer marketing exclusivity on generic versions of Merck & Co's antihypertensives, Cozaar (losartan potassium) and Hyzaar (losartan plus hydrochlorothiazide).

The US FDA has filed a motion to dismiss Teva Pharmaceutical Industries' recent lawsuit regarding the loss of its first-filer marketing exclusivity on generic versions of Merck & Co's antihypertensives, Cozaar (losartan potassium) and Hyzaar (losartan plus hydrochlorothiazide).

Teva has pending ANDAs for its generic versions, and the case involves a situation where a brand firm has voluntarily...

Welcome to Scrip

Create an account to read this article

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip